BI
JSPR icon

BVF Inc’s Jasper Therapeutics JSPR Stock Holding History

BVF Inc’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-990,000
Closed -$6.93M – 73
2023
Q3 		$6.93M Hold
990,000
– – 0.19% 50
2023
Q2 		$13.6M Hold
990,000
– – 0.38% 40
2023
Q1 		$17.9M Buy
+990,000
New +$18.3M 0.66% 40

Other funds holding JSPR

ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

BVF Inc's JSPR Position: Q4 2023 in Review

BVF Inc sold out of Jasper Therapeutics (JSPR) in Q4 2023, closing a stake of 990,000 shares — an estimated $6.93M sold.

BVF Inc first reported a position in JSPR in Q1 2023 and held it in 3 quarters. The position peaked at $17.9M in Q1 2023. 41 funds tracked by Wall St. Rank hold JSPR as of Q4 2023.

  • BVF Inc reported no remaining Jasper Therapeutics position as of Q4 2023 after selling out during the quarter.
  • BVF Inc sold 990,000 Jasper Therapeutics shares in Q4 2023, an estimated $6.93M.
  • BVF Inc first reported a position in Jasper Therapeutics in Q1 2023 and held it in 3 quarters.
  • BVF Inc's Jasper Therapeutics position peaked at $17.9M in Q1 2023.
  • 41 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2023.

Based on BVF Inc's 13F filing for Q4 2023, filed 14 Feb 2024.